Abstract
Recombinant adeno-associated virus (rAAV) vectors possess a number of properties that may make them suitable for clinical gene therapy, including being based upon a virus for which there is no known pathology and a natural propensity to persist in human cells. Wild-type adeno-associated viruses (AAVs) are now known to be very diverse and ubiquitous in humans and nonhuman primates, which adds to the degree of confidence one may place in the natural history of AAV, namely that it has never been associated with any human tumors or other acute pathology, other than sporadic reports of having been isolated from spontaneously aborted fetuses. On the basis of this understanding of AAV biology and a wide range of preclinical studies in mice, rabbits, dogs and nonhuman primates, a growing number of clinical trials have been undertaken with this class of vectors. Altogether, over 40 clinical trials have now been approved. Although all previous trials were undertaken using AAV serotype 2 vectors, at least two current trials utilize AAV2 vector genomes cross-packaged or pseudotyped into AAV1 capsids, which appear to mediate more efficient gene delivery to muscle. The explosion of capsid isolates available for use as vectors to over 120 has now provided the potential to broaden the application of AAV-based gene therapy to other cell types.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7: 1145–1159.
Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257–261.
Rubenstein RC, McVeigh U, Flotte TR, Guggino WB, Zeitlin PL . CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector. Gene Therapy 1997; 4: 384–392.
Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Therapy 1996; 3: 658–668.
Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR . Latent adeno-associated virus infection elicits humoral but not cell- mediated immune responses in a nonhuman primate model [In Process Citation]. J Virol 1999; 73: 8549–8558.
Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70: 3235–3241.
Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14: 1079–1088.
Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB . Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther 2005; 16: 921–928.
Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109: 266–274.
Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001; 12: 1907–1916.
Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509–521.
Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007; 18: 726–732.
Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13: 1349–1359.
Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5: 64–70.
Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM . Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 3906–3910.
Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE . Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619–623.
Hagstrom JN, Couto LB, Scallan C, Burton M, McCleland ML, Fields PA et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 2000; 95: 2536–2542.
Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963–2972.
Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342–347.
Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92–95.
Narfstrom K, Katz ML, Ford M, Redmond TM, Rakoczy E, Bragadottir R . In vivo gene therapy in young and adult RPE65−/− dogs produces long-term visual improvement. J Hered 2003; 94: 31–37.
Narfstrom K, Katz ML, Bragadottir R, Seeliger M, Boulanger A, Redmond TM et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 2003; 44: 1663–1672.
Jacobson SG, Acland GM, Aguirre GD, Aleman TS, Schwartz SB, Cideciyan AV et al. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006; 13: 1074–1084.
Jacobson SG, Boye SL, Aleman TS, Conlon TJ, Zeiss CJ, Roman AJ et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 2006; 17: 845–858.
Leone P, Janson CG, Bilaniuk L, Wang Z, Sorgi F, Huang L et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease [see comments] [published erratum appears in Ann Neurol 2000 Sep;48(3):398]. Ann Neurol 2000; 48: 27–38.
Leone P, Janson CG, McPhee SJ, During MJ . Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease. Curr Opin Mol Ther 1999; 1: 487–492.
McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577–588.
Hornykiewicz O, Kish SJ . Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19–34.
Mochizuki H, Mizuno Y . Gene therapy for Parkinson's disease. J Neural Transm Suppl 2003: 205–213.
Mandel RJ, Spratt SK, Snyder RO, Leff SE . Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997; 94: 14083–14088.
Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Macias R, Alvarez L, Guridi J et al. Pathophysiologic basis of surgery for Parkinson's disease. Neurology 2000; 55: S7–S12.
Wichmann T, DeLong MR . Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci 2003; 991: 199–213.
Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 19559–19564.
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097–2105.
Forsayeth JR, Eberling JL, Sanftner LM, Zhen Z, Pivirotto P, Bringas J et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 2006; 14: 571–577.
Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564–570.
Mandel RJ, Gage FH, Clevenger DG, Spratt SK, Snyder RO, Leff SE . Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp Neurol 1999; 155: 59–64.
Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 2004; 15: 1131–1154.
Jennings K, Miyamae T, Traister R, Marinov A, Katakura S, Sowders D et al. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther 2005; 11: 600–607.
Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14384–14388.
Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR . Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2001; 8: 1299–1306.
Song S, Scott-Jorgensen M, Wang J, Poirier A, Crawford J, Campbell-Thompson M et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002; 6: 329–335.
Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 15: 93–128.
Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE . Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 2001; 4: 217–222.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mueller, C., Flotte, T. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15, 858–863 (2008). https://doi.org/10.1038/gt.2008.68
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2008.68
Keywords
This article is cited by
-
A mosaic adeno-associated virus vector as a versatile tool that exhibits high levels of transgene expression and neuron specificity in primate brain
Nature Communications (2023)
-
Reversibility of motor dysfunction in the rat model of NGLY1 deficiency
Molecular Brain (2021)
-
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Scientific Reports (2020)
-
Analysis of recombinant adeno-associated viral vector shedding in sheep following intracoronary delivery
Gene Therapy (2019)
-
Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract
Gene Therapy (2017)